(RTTNews) – Pfizer Inc.(PFE) Executive Director Albert Bourla said an update on the complex trial of his candidate coronavirus vaccine (COVID-19) may be provided as of October 2020.
“We are at a very complex stage” and have already recruited 23,000 of the 30,000 volunteer patients needed for the “big fundamental trial” of Phase 3 that began in late July, he said.
Bourla speaking Thursday at the virtual press conference of the CEO / Top Execs of Global Biopharma – COVID-19 Therapeutics organized through the International Federation of Associations and Pharmaceutical Manufacturers (IFPMA). IFPMA represents research-based pharmaceutical corporations and associations around the world.
IFPMA held a virtual press conference with CEOs and executives who are at the forefront of the R
Pfizer is jointly developing the candidate BNT 162 vaccine with German drug manufacturer BioNTech SE (BNTX).BNT162 is an mNR-based candidate vaccine for SARS-CoV2.
The BNT162 program is based on BioNTech’s patented mNR generation and is backed by Pfizer’s global vaccine production and progression capabilities.
Bourla said he hoped to know if the vaccine would work, until the end of October, and planned to send it for authorization or approval to the U.S. Food and Drug Administration at the same time, assuming success.Clinical.
However, Bourla demonstrated that it will “not cut” in accelerating the vaccination procedure and that the effects of the Phase 3 review will serve as the basis for the submission of approval or approval.He confided that “we will never present a vaccine ourselves for approval or approval until we believe it is effective.”
Pfizer recently announced plans to obtain up to one hundred million international doses by the end of 2020 and approximately 1.3 billion doses by the end of 2021.